<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Fluocinolone (ophthalmic): Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Fluocinolone (ophthalmic): Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Fluocinolone (ophthalmic): Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="97768" href="/d/html/97768.html" rel="external">see "Fluocinolone (ophthalmic): Patient drug information"</a> and <a class="drug drug_pediatric" data-topicid="15988" href="/d/html/15988.html" rel="external">see "Fluocinolone (ophthalmic): Pediatric drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F8097409"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Iluvien;</li>
<li>Retisert;</li>
<li>Yutiq</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52869157"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Retisert</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F8097453"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Corticosteroid, Ophthalmic</li></ul></div>
<div class="block doa drugH1Div" id="F8100694"><span class="drugH1">Dosing: Adult</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="867af98d-205e-460e-8955-a72b16570934">Diabetic macular edema</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Diabetic macular edema:</b> Ocular implant (Iluvien): Intravitreal injection: One implant (0.19 mg) injected in affected eye. <b>Note:</b> Implant is designed to release fluocinolone at an initial rate of 0.25 mcg daily lasting 36 months.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="571054ef-6fb3-4677-9101-4840672bf0aa">Uveitis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Uveitis (chronic):</b></p>
<p style="text-indent:-2em;margin-left:4em;">Ocular implant (Retisert): Intravitreal injection: One silicone-encased tablet (0.59 mg) surgically implanted into the posterior segment of the affected eye. <b>Note:</b> Implant is designed to initially release 0.6 mcg/day, decreasing over 30 days to a steady-state release rate of 0.3 to 0.4 mcg daily for ~30 months. Recurrence of uveitis denotes depletion of tablet, requiring reimplantation.</p>
<p style="text-indent:-2em;margin-left:4em;">Ocular implant (Yutiq): Intravitreal injection: One implant (0.18 mg) injected in affected eye. <b>Note:</b> Implant is designed to release fluocinolone at an initial rate of 0.25 mcg daily lasting 36 months.</p></div>
</div>
</div>
<div class="block dora drugH1Div" id="F50991159"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer’s labeling. </p></div>
<div class="block doha drugH1Div" id="F50988521"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer’s labeling. </p></div>
<div class="block doe drugH1Div" id="F8100695"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block dop drugH1Div" id="F8100693"><span class="drugH1">Dosing: Pediatric</span><p>(For additional information <a class="drug drug_pediatric" data-topicid="15988" href="/d/html/15988.html" rel="external">see "Fluocinolone (ophthalmic): Pediatric drug information"</a>)</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="1c9e82ff-62d1-4860-96f2-1699375716c6">Uveitis, chronic</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Uveitis, chronic:</b> Children ≥12 years and Adolescents: Ocular implant (Retisert): Intravitreal injection: One silicone-encased tablet (0.59 mg) surgically implanted into the posterior segment of the affected eye. <b>Note:</b> Implant is designed to release 0.6 mcg/day, decreasing over 30 days to a steady-state release rate of 0.3 to 0.4 mcg daily for 30 months. Recurrence of uveitis denotes depletion of tablet, requiring reimplantation.</p></div>
</div>
</div>
<div class="block dorp drugH1Div" id="F51111038"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block dohp drugH1Div" id="F51111039"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block adr drugH1Div" id="F8097484"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">Iluvien:</p>
<p style="text-indent:-2em;margin-left:4em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:6em;">Hematologic &amp; oncologic: Anemia (11%)</p>
<p style="text-indent:-2em;margin-left:6em;">Ophthalmic: Cataract (82%), conjunctival hemorrhage (13%), eye pain (15%), increased intraocular pressure (≥10 mm Hg: 34%; ≥30 mm Hg: 20%), vitreous opacity (21%)</p>
<p style="text-indent:-2em;margin-left:4em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:6em;">Nervous system: Headache (9%)</p>
<p style="text-indent:-2em;margin-left:6em;">Ophthalmic: Conjunctivitis (4%), corneal edema (4%), eye discharge (2%), eye discomfort (2%), eye irritation (8%), eye pruritus (3%), foreign body sensation of eye (3%), ocular hyperemia (3%), ophthalmic signs and symptoms (anterior chamber cell: 2%), optic atrophy (2%), photophobia (2%), retinal exudates (2%), secondary cataract (9%)</p>
<p style="text-indent:-2em;margin-left:6em;">Renal: Renal failure syndrome (9%)</p>
<p style="text-indent:-2em;margin-left:6em;">Respiratory: Pneumonia (7%)</p>
<p style="text-indent:-2em;margin-left:2em;">Retisert:</p>
<p style="text-indent:-2em;margin-left:4em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:6em;">Dermatologic: Skin rash (5% to 20%)</p>
<p style="text-indent:-2em;margin-left:6em;">Gastrointestinal: Nausea (5% to 20%), vomiting (5% to 20%)</p>
<p style="text-indent:-2em;margin-left:6em;">Infection: Influenza (5% to 20%)</p>
<p style="text-indent:-2em;margin-left:6em;">Nervous system: Dizziness (5% to 20%), headache (33%)</p>
<p style="text-indent:-2em;margin-left:6em;">Neuromuscular &amp; skeletal: Arthralgia (5% to 20%), back pain (5% to 20%), limb pain (5% to 20%)</p>
<p style="text-indent:-2em;margin-left:6em;">Ophthalmic: Abnormal sensation in eyes (10% to 40%), blepharoptosis (10% to 40%), blurred vision (10% to 40%), cataract (50% to 90%), conjunctival hemorrhage (10% to 40%), conjunctival hyperemia (10% to 40%), decreased visual acuity (10% to 40%), dry eye syndrome (10% to 40%), eye irritation (10% to 40%), eye pain (50% to 90%), eye pruritus (10% to 40%), eyelid edema (10% to 40%), glaucoma (10% to 40%), hypotony of eye (10% to 40%), increased intraocular pressure (50% to 90%), lacrimation (10% to 40%), macular edema (10% to 40%), maculopathy (10% to 40%), ocular hyperemia (10% to 40%), visual disturbance (10% to 40%), vitreous opacity (10% to 40%), vitreous hemorrhage (10% to 40%)</p>
<p style="text-indent:-2em;margin-left:6em;">Respiratory: Cough (5% to 20%), nasopharyngitis (5% to 20%), sinusitis (5% to 20%), upper respiratory tract infection (5% to 20%)</p>
<p style="text-indent:-2em;margin-left:6em;">Miscellaneous: Fever (5% to 20%)</p>
<p style="text-indent:-2em;margin-left:4em;">1% to 10%: Ophthalmic: Anterior chamber eye hemorrhage (5% to 9%), blepharitis (5% to 9%), choroidal detachment (5% to 9%), corneal edema (5% to 9%), diplopia (5% to 9%), eye discharge (5% to 9%), photophobia (5% to 9%), photopsia (5% to 9%), retinal detachment (5% to 9%), retinal hemorrhage (5% to 9%), swelling of eye (5% to 9%), synechiae of iris (5% to 9%)</p>
<p style="text-indent:-2em;margin-left:2em;">Yutiq:</p>
<p style="text-indent:-2em;margin-left:4em;">&gt;10%: Ophthalmic: Cataract (56%), decreased visual acuity (15%), increased intraocular pressure (≥10 mm Hg: 22%; ≥30 mm Hg: 12%)</p>
<p style="text-indent:-2em;margin-left:4em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:6em;">Cardiovascular: Hypertension (3%)</p>
<p style="text-indent:-2em;margin-left:6em;">Neuromuscular &amp; skeletal: Arthralgia (2%)</p>
<p style="text-indent:-2em;margin-left:6em;">Ophthalmic: Conjunctival hemorrhage (8%), dry eye syndrome (4%), eye discomfort (2%), foreign body sensation of eye (3%), glaucoma (2%), hypotony of eye (7%), lacrimation (1%), secondary cataract (4%), visual field defect (1%), vitreous hemorrhage (2%)</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined (any formulation): Ophthalmic: Endophthalmitis (including late onset), ophthalmic inflammation</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing (any formulation): Ophthalmic: Retinitis (viral) (Takakura 2014), sclera disease (including scleral melt and scleral thinning) (Georgalas 2014), viral corneal disease (cytomegalovirus endotheliitis) (Sims 2010) vitreous disorder (bands) (Georgalas 2014)</p></div>
<div class="block coi drugH1Div" id="F8097466"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">Hypersensitivity to fluocinolone, other corticosteroids, or any component of the formulation; active or suspected ocular or periocular infections including most viral diseases of the cornea and conjunctiva including epithelial herpes simplex keratitis (dendritic keratitis), vaccinia, and varicella; active bacterial, mycobacterial or fungal infections of the eye.</p>
<p style="text-indent:-2em;margin-left:2em;margin-top:0em;">Iluvien only: Glaucoma (in patients who have cup to disc ratios of &gt;0.8).</p></div>
<div class="block war drugH1Div" id="F8097467"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Cataract formation: Use of corticosteroids may result in posterior subcapsular cataract formation.</p>
<p style="text-indent:-2em;margin-left:4em;">• Glaucoma: Use of corticosteroids (especially long-term use) may cause increased intraocular pressure and glaucoma. Use with caution in patients with glaucoma. Monitor IOP in all patients; within 3 years postimplantation, most patients will require IOP lowering medications and/or filtering procedures to control IOP.</p>
<p style="text-indent:-2em;margin-left:4em;">• Immunosuppression: May enhance development of secondary bacterial, fungal, or viral infections. Not recommended in patients with a history of ocular herpes simplex (potential for reactivation). Use with caution in patients with a history of bacterial, mycobacterial, fungal, or viral infections or the cornea and conjunctiva including epithelial herpes simplex keratitis (dendritic keratitis), vaccinia, and varicella. In acute purulent conditions, may mask infection. Fungal and viral infections are of particular concern. If corneal ulceration persists, consider fungal infection.</p>
<p style="text-indent:-2em;margin-left:4em;">• Ocular effects: Intravitreal injections have been associated with endophthalmitis, eye inflammation, increased intraocular pressure and retinal detachment. Monitor carefully after intravitreal injection. Complications may also include cataract formation, choroidal detachment, hypotony, vitreous hemorrhage, vitreous loss, and wound dehiscence. Procedure may cause optic nerve injury. Visual defects in acuity and field of vision may occur (lasting 1 to 4 weeks postoperatively). Late-onset endophthalmitis has been observed, often associated with surgical site integrity.</p>
<p style="text-indent:-2em;margin-left:4em;">• Ocular effects: Retisert: Perforation may occur with topical steroids in diseases which thin the cornea or sclera. Steroid use may delay healing after cataract surgery and increase bleb formation incidence.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Dosage form specific issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Ocular implant: Iluvien, Yutiq: In patients in whom the posterior capsule of the lens is absent or has a tear, implant may migrate into the anterior chamber.</p>
<p style="text-indent:-2em;margin-left:4em;">• Ocular implant: Retisert: Recommend unilateral implantation only to minimize risk of postoperative infections developing in both eyes. Due to the potential for separation of the silicone cup reservoir from the suture tab, implant integrity should be monitored during eye exams. Assure tight closure of scleral wound and integrity of overlying conjunctiva at the wound site.</p></div>
<div class="block foc drugH1Div" id="F8100720"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Implant, Intravitreal, as acetonide: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Iluvien: 0.19 mg (1 ea)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Retisert: 0.59 mg (1 ea)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Yutiq: 0.18 mg (1 ea)</p></div>
<div class="block geq drugH1Div" id="F8097451"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">No</p></div>
<div class="block fee drugH1Div" id="F16322153"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Implant</b> (Iluvien Intravitreal)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.19 mg (per each): $10,560.00</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Implant</b> (Retisert Intravitreal)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.59 mg (per each): $22,830.00</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Implant</b> (Yutiq Intravitreal)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.18 mg (per each): $10,795.20</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52869158"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Implant, Intravitreal, as acetonide: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Retisert: 0.59 mg (1 ea)</p></div>
<div class="block adm drugH1Div" id="F8100697"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">Ophthalmic implant (intravitreal injection): Administer under controlled aseptic conditions (eg, sterile gloves, sterile drape, sterile eyelid speculum). Administer adequate anesthesia and a broad-spectrum bactericidal to the periocular skin, eyelid, and ocular surfaces prior to injection. Refer to manufacturer’s prescribing information for administration technique.</p>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">Iluvien: Visually inspect preloaded applicator to ensure that it contains a drug implant. Optimal placement is inferior to optic disc and posterior to the equator of the eye</p>
<p style="text-indent:-2em;margin-left:2em;">Retisert: Handle only by suture tab to avoid damaging the tablet integrity and adversely affecting release characteristics; avoid sheer forces on implant. Do not resterilize.</p>
<p style="text-indent:-2em;margin-left:2em;">Yutiq: Optimal placement is inferior to optic disc and posterior to the equator of the eye.</p></div>
<div class="block admp drugH1Div" id="F52614348"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Ophthalmic: Intravitreal injection: Administer under controlled aseptic conditions (eg, sterile gloves, sterile drape, sterile eyelid speculum). Administer adequate anesthesia and a broad-spectrum bactericidal to the periocular skin, eyelid, and ocular surfaces prior to injection. Refer to manufacturer's prescribing information for administration technique.</p>
<p style="text-indent:-2em;margin-left:2em;">Retisert: Handle only by suture tab to avoid damaging the tablet integrity and adversely affecting release characteristics. Do not resterilize.</p></div>
<div class="block use drugH1Div" id="F8097411"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Diabetic macular edema (Iluvien):</b> Treatment of diabetic macular edema in patients who have been previously treated with a course of corticosteroids and did not have a clinically significant rise in intraocular pressure.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Uveitis (Retisert, Yutiq):</b> Treatment of chronic, noninfectious uveitis affecting the posterior segment of the eye</p></div>
<div class="block mst drugH1Div" id="F8097406"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues: </span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Fluocinolone may be confused with fluocinonide</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F13299347"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F8097492"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Nonsteroidal Anti-Inflammatory Agents (Ophthalmic): May enhance the adverse/toxic effect of Corticosteroids (Ophthalmic). Healing of ophthalmic tissue during concomitant administration of ophthalmic products may be delayed.<i> Risk C: Monitor therapy</i></p></div>
<div class="block pri drugH1Div" id="F8097462"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;display:inline">Animal studies have not been conducted with this product; however, adverse events have been observed with corticosteroids in animal reproduction studies. Systemic absorption is below the limit of quantification following ocular administration.</p></div>
<div class="block brc drugH1Div" id="F8097465"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">Systemic corticosteroids are present in breast milk.</p>
<p style="text-indent:-2em;margin-left:2em;">It is not known if sufficient quantities of fluocinolone are absorbed following ocular administration to produce detectable amounts in breast milk; however, systemic absorption is below the limit of quantification. The decision to breastfeed during therapy should consider the risk of infant exposure, the benefits of breastfeeding to the infant, and benefits of treatment to the mother.</p></div>
<div class="block mop drugH1Div" id="F27107187"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:-2em;margin-left:2em;">Iluvien, Yutiq: Following injection, monitor for increased intraocular pressure and endophthalmitis; check for perfusion of optic nerve head immediately after injection, tonometry within 30 minutes, and biomicroscopy between 2 to 7 days after injection.</p>
<p style="text-indent:-2em;margin-left:2em;">Retisert: Periodically monitor integrity of implant by visual inspection; recurrence of uveitis (may indicate need for reimplantation); IOP.</p></div>
<div class="block pha drugH1Div" id="F27107011"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Inhibit phospholipase A<sub>2</sub> via lipocortin induction   Lipocortins may control biosynthesis of prostaglandins and leukotrienes by inhibiting arachidonic acid.  Arachidonic acid is released by membrane phospholipids by phospholipase A<sub>2</sub>.</p></div>
<div class="block phk drugH1Div" id="F8100684"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Duration:</p>
<p style="text-indent:-2em;margin-left:4em;">Iluvien, Yutiq: Releases fluocinolone acetonide at an initial rate of 0.25 mcg/day for 36 months</p>
<p style="text-indent:-2em;margin-left:4em;">Retisert: Releases fluocinolone acetonide at an initial rate of 0.6 mcg/day, decreasing over 30 days to a steady-state release rate of 0.3 to 0.4 mcg/day for 30 months</p>
<p style="text-indent:-2em;margin-left:2em;">Absorption: Systemic absorption is negligible</p>
<p style="text-indent:-2em;margin-left:2em;">Distribution: Retisert: Aqueous and vitreous humor</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F23777413"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Iluvien</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Iluvien</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Iluvien</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Iluvien</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Yutiq</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Iluvien</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-25489235">
<a name="25489235"></a>Georgalas I, Koutsandrea C, Papaconstantinou D, Mpouritis D, Petrou P. Scleral melt following Retisert intravitreal fluocinolone implant. <i>Drug Des Devel Ther</i>. 2014;8:2373-2375. doi:10.2147/DDDT.S66634<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluocinolone-ophthalmic-drug-information/abstract-text/25489235/pubmed" id="25489235" target="_blank">25489235</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Iluvien (fluocinolone) [prescribing information]. Alpharetta, GA: Alimera Sciences Inc; January 2022.</div>
</li>
<li>
<div class="reference">
                  Retisert (fluocinolone) [prescribing information]. Bridgewater, NJ: Bausch &amp; Lomb Incorporated; January 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19325574">
<a name="19325574"></a>Sims JL, Chee SP. Cytomegalovirus endotheliitis following fluocinolone acetonide (Retisert) implant. <i>Eye (Lond)</i>. 2010;24(1):197-198. doi:10.1038/eye.2009.54<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluocinolone-ophthalmic-drug-information/abstract-text/19325574/pubmed" id="19325574" target="_blank">19325574</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24655372">
<a name="24655372"></a>Takakura A, Tessler HH, Goldstein DA, et al. Viral retinitis following intraocular or periocular corticosteroid administration: a case series and comprehensive review of the literature. <i>Ocul Immunol Inflamm</i>. 2014;22(3):175-182. doi:10.3109/09273948.2013.866256<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluocinolone-ophthalmic-drug-information/abstract-text/24655372/pubmed" id="24655372" target="_blank">24655372</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Yutiq.2018.10">
<a name="Yutiq.2018.10"></a>Yutiq (fluocinolone acetonide intravitreal implant) [prescribing information]. Watertown, MA: EyePoint Pharmaceuticals US Inc; February 2022.</div>
</li></ol></div><div id="topicVersionRevision">Topic 9128 Version 155.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
